Mutational landscape and genetic signatures of cell‐free DNA in tumour‐induced osteomalacia

Tumour‐induced osteomalacia (TIO) is a very rare paraneoplastic syndrome with bone pain, fractures and muscle weakness, which is mostly caused by phosphaturic mesenchymal tumours (PMTs). Cell‐free DNA (cfDNA) has been regarded as a non‐invasive liquid biopsy for many malignant tumours. However, it has not been studied in benign tumours, which prompted us to adopt the targeted next‐generation sequencing approach to compare cfDNAs of 4 TIO patients, four patients with bone metastasis (BM) and 10 healthy controls. The mutational landscapes of cfDNA in TIO and BM groups were similar in the spectrum of allele frequencies and mutation types. Markedly, deleterious missense mutations in FGFR1 and loss‐of‐function mutations in MED12 were found in 3/4 TIO patients but none of BM patients. The gene ontology analysis strongly supported that these mutated genes found in TIOs would play a potential role in PMTs' process. The genetic signatures and corresponding change in expression of FGFR1 and FGF23 were further validated in PMT tissues from a test cohort of another three TIO patients. In summary, we reported the first study of the mutational landscape and genetic signatures of cfDNA in TIO/PMTs.

[1]  A. Molinolo,et al.  Tumor-induced osteomalacia. , 2011, Endocrine-related cancer.

[2]  Leah M Chase,et al.  Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma , 2019, Clinical Cancer Research.

[3]  Crispin J. Miller,et al.  Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study , 2019, Nature Medicine.

[4]  G. Song,et al.  Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing , 2018, Molecular Cancer.

[5]  X. Yi,et al.  Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance , 2018, EBioMedicine.

[6]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[7]  Atul J Butte,et al.  Comprehensive analysis of normal adjacent to tumor transcriptomes , 2017, Nature Communications.

[8]  K. Sargar,et al.  Imaging of Skeletal Disorders Caused by Fibroblast Growth Factor Receptor Gene Mutations. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[9]  M. Collins,et al.  Tumour-induced osteomalacia , 2017, Nature Reviews Disease Primers.

[10]  L. Wood,et al.  Cancer‐Associated Mutations in Endometriosis without Cancer , 2017, The New England journal of medicine.

[11]  Grace Q. Zhao,et al.  Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma , 2017, Theranostics.

[12]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[13]  The Gene Ontology Consortium,et al.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[14]  Konstantinos Konstantopoulos,et al.  Cancer cell motility: lessons from migration in confined spaces , 2016, Nature Reviews Cancer.

[15]  Pedro P. Rocha,et al.  MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis. , 2016, Cell stem cell.

[16]  A. Folpe,et al.  Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors , 2016, Modern Pathology.

[17]  Steven P. Gygi,et al.  Defining the consequences of genetic variation on a proteome-wide scale , 2016, Nature.

[18]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[19]  R. Grose,et al.  Dysregulated FGF signalling in neoplastic disorders. , 2016, Seminars in cell & developmental biology.

[20]  Maurizio Scaltriti,et al.  Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy , 2016, Clinical Cancer Research.

[21]  S. Fukumoto FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism , 2016, Calcified Tissue International.

[22]  N. Malats,et al.  Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer , 2015, BMC Cancer.

[23]  X. Weng,et al.  Surgical Treatments of Tumor-Induced Osteomalacia Lesions in Long Bones: Seventeen Cases with More Than One Year of Follow-up. , 2015, The Journal of bone and joint surgery. American volume.

[24]  S. Noguchi,et al.  Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing , 2015, Breast Cancer Research and Treatment.

[25]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[26]  A. Folpe,et al.  Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour , 2015, The Journal of pathology.

[27]  Ash A. Alizadeh,et al.  FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution , 2014, Bioinform..

[28]  O. Kallioniemi,et al.  FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data , 2014, bioRxiv.

[29]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[30]  Swe Swe Myint,et al.  Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma , 2014, Nature Genetics.

[31]  H. Walden,et al.  The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. , 2014, Annual review of biophysics.

[32]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[33]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  杨凌春,et al.  Broad Institute , 2014 .

[35]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[36]  A. Dwyer,et al.  Tumor localization and biochemical response to cure in tumor‐induced osteomalacia , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[38]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[39]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[40]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[41]  A. Gill,et al.  Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. , 2013, The Journal of clinical endocrinology and metabolism.

[42]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[43]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[44]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[45]  L. Aaltonen,et al.  MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas , 2011, Science.

[46]  Klaus Pantel,et al.  Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. , 2011, Molecular bioSystems.

[47]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[48]  A. Molinolo,et al.  Tumor-induced osteomalacia. , 2011, Endocrine-related cancer.

[49]  P. Andreopoulou,et al.  Selective Venous Catheterization for the Localization of Phosphaturic Mesenchymal Tumors , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[51]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[52]  Yibo Wu,et al.  GOSemSim: an R package for measuring semantic similarity among GO terms and gene products , 2010, Bioinform..

[53]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[54]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[55]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[56]  J. D. Engel,et al.  GATA1-related leukaemias , 2008, Nature Reviews Cancer.

[57]  K. Nanjo,et al.  Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. , 2008, Internal medicine.

[58]  J. Opitz,et al.  A recurrent mutation in MED12 leading to R961W causes Opitz-Kaveggia syndrome , 2007, Nature Genetics.

[59]  S. Mooney,et al.  Extended mutational analyses of FGFR1 in osteoglophonic dysplasia , 2006, American journal of medical genetics. Part A.

[60]  C. Vandenberg,et al.  The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair , 2005, Nature Genetics.

[61]  O. Blagosklonov,et al.  Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. , 2005, Bone.

[62]  K. White,et al.  Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. , 2005, American journal of human genetics.

[63]  A. Uitterlinden,et al.  Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. , 2004, JAMA.

[64]  W. J. Kent,et al.  BLAT--the BLAST-like alignment tool. , 2002, Genome research.

[65]  N. Watts,et al.  Localisation of mesenchymal tumours by somatostatin receptor imaging , 2002, The Lancet.

[66]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.